Skip to main content
JOHNSON & JOHNSON logo

JOHNSON & JOHNSON — Investor Relations & Filings

Ticker · JNJ ISIN · US4781601046 LEI · 549300G0CFPGEF6X2043 US Manufacturing
Open in API
Filings indexed 3,105 across all filing types
Latest filing 2017-09-15 Director's Dealing
Country US United States of America
Listing US JNJ

About JOHNSON & JOHNSON

https://www.jnj.com/

Johnson & Johnson is a healthcare company that operates through two primary segments: Innovative Medicine and MedTech. The Innovative Medicine division is focused on the research, development, and delivery of new treatments for complex diseases in areas such as oncology, immunology, neuroscience, and cardiopulmonary conditions. The MedTech segment develops and provides a broad portfolio of medical technologies and solutions. It innovates in fields including surgery, orthopaedics, vision, and interventional solutions, aiming to create smarter, less invasive, and more personalized healthcare treatments. The company's mission is to address significant health challenges through science-based innovation at the intersection of biology and technology.

Recent filings

Filing Released Lang Actions
Director's Dealing 2017
Director's Dealing
2017-09-15 English
PRIMARY DOCUMENT
Director's Dealing
2017-09-14 English
FORM SC 13G/A FOR MINERVA NEUROSCIENCES, INC. BY JOHNSON & JOHNSON
Major Shareholding Notification
2017-09-14 English
8-K/A
Regulatory Filings Classification · 95% confidence The document is a Form 8-K/A, which is an amendment to a previously filed Form 8-K. It reports the completion of an acquisition (Actelion Ltd by Johnson & Johnson) and includes financial statements of the business acquired and pro forma financial information. The document is not a full annual or quarterly report but an SEC current report amendment related to a specific event (acquisition). It contains audited financial statements of the acquired company and pro forma combined financials, which are typical exhibits in acquisition-related filings. The document length is 4038 characters, which is relatively short and focused on the acquisition event and related financial disclosures. This fits best under the category of a Regulatory Filing (RNS) because it is an SEC current report amendment providing event-specific financial information rather than a full annual report or standalone audit report. It is not a merger proxy statement or tender offer filing (MA or TAR), but an 8-K/A amendment. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2017-08-29 English
10-Q 2Q 2017
Interim / Quarterly Report Q2 2017
2017-08-03 English
Director's Dealing 2017
Director's Dealing
2017-07-26 English

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.